Condition
CCR5
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Withdrawn2
Clinical Trials (2)
Showing 2 of 2 trials
NCT05730673Phase 2WithdrawnPrimary
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
NCT02990312Phase 4Withdrawn
Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
Showing all 2 trials